MicroRNAs in tumor exosomes drive immune escape in melanoma
Cancer Immunology Research, ISSN: 2326-6074, Vol: 8, Issue: 2, Page: 255-267
2020
- 109Citations
- 70Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations109
- Citation Indexes109
- 109
- CrossRef55
- Captures70
- Readers70
- 70
- Mentions2
- News Mentions2
- News2
Most Recent News
Exosomes: Key Messengers Mediating the Interaction Between Tumor Cells and CD8+ T Cells in the Tumor Microenvironment
Introduction Exosomes are a type of extracellular vesicles with a diameter of approximately 30–150 nanometers, which are released by various cell types into the extracellular
Article Description
MicroRNAs (miRNA), small noncoding RNAs that regulate gene expression, exist not only in cells but also in a variety of body fluids. These circulating miRNAs could enable intercellular communication. miRNAs are packaged in membrane-encapsulated vesicles, such as exosomes, or protected by RNA-binding proteins. Here, we report that miRNAs included in human melanoma exosomes regulate the tumor immune response. Using microscopy and flow cytometry, we demonstrate that CD8 T cells internalize exosomes from different tumor types even if these cells do not internalize vesicles as readily as other immune cells. We explored the function of melanoma-derived exosomes in CD8 T cells and showed that these exosomes downregulate T-cell responses through decreased T-cell receptor (TCR) signaling and diminished cytokine and granzyme B secretions. The result reduces the cells’ cytotoxic activity. Using mimics, we found that miRNAs enriched in exosomes—such as Homo sapiens (hsa)-miR-3187-3p, hsa-miR-498, hsa-miR-122, hsa-miR149, and hsa-miR-181a/b—regulate TCR signaling and TNFα secretion. Our observations suggest that miRNAs in melanoma-derived exosomes aid tumor immune evasion and could be a therapeutic target.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079018393&origin=inward; http://dx.doi.org/10.1158/2326-6066.cir-19-0522; http://www.ncbi.nlm.nih.gov/pubmed/31857348; https://aacrjournals.org/cancerimmunolres/article/8/2/255/469585/MicroRNAs-in-Tumor-Exosomes-Drive-Immune-Escape-in; https://dx.doi.org/10.1158/2326-6066.cir-19-0522
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know